Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

First In Human (FIH) Study of REGN5459 in Adult Patients With Relapsed or Refractory Multiple Myeloma (MM)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04083534
Recruitment Status : Recruiting
First Posted : September 10, 2019
Last Update Posted : June 15, 2021
Sponsor:
Information provided by (Responsible Party):
Regeneron Pharmaceuticals

Brief Summary:

In the phase 1 portion of the study, the primary objectives are to assess the safety, tolerability, and dose-limiting toxicities (DLTs) and to determine a recommended phase 2 dose regimen (RP2DR) of REGN5459 as monotherapy in patients with relapsed or refractory multiple myeloma (MM) who have exhausted all therapeutic options that are expected to provide meaningful clinical benefit.

In the phase 2 portion of the study, the primary objective is to assess the preliminary anti-tumor activity of REGN5459 as measured by objective response rate (ORR).

In the phase 1 and phase 2 portion, the secondary objectives of the study are:

  • To assess the preliminary anti-tumor activity of REGN5459 as measured by duration of response (DOR), progression-free survival (PFS), rate of minimal residual disease (MRD) negative status, and overall survival (OS)
  • To evaluate the pharmacokinetic (PK) properties of REGN5459
  • To characterize the immunogenicity of REGN5459
  • To evaluate the effects of REGN5459 on patient-reported quality of life (QoL), symptoms, functioning and general health status

In the phase 1 portion of the study only, the secondary objective of the study is to assess the preliminary anti-tumor activity of REGN5459 as measured by ORR.

In the phase 2 portion of the study only, the secondary objective of the study is to evaluate the safety and tolerability of REGN5459.


Condition or disease Intervention/treatment Phase
Relapsed Multiple Myeloma Refractory Multiple Myeloma Drug: REGN5459 Phase 1 Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 70 participants
Allocation: N/A
Intervention Model: Sequential Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase 1/2 FIH Study of REGN5459 (Anti-BCMA x Anti-CD3 Bispecific Antibody) in Patients With Relapsed or Refractory Multiple Myeloma
Actual Study Start Date : September 26, 2019
Estimated Primary Completion Date : February 14, 2025
Estimated Study Completion Date : March 19, 2025

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Multiple Myeloma

Arm Intervention/treatment
Experimental: REGN5459
Cohorts of multiple REGN5459 dose levels
Drug: REGN5459
Administered by intravenous (IV) infusion




Primary Outcome Measures :
  1. Incidence of dose-limiting toxicities (DLTs) from the first dose through the end of the DLT observation period [ Time Frame: Up to 35 Days ]
    Phase 1

  2. Incidence and severity of treatment-emergent adverse events (TEAEs) during REGN5459 treatment period [ Time Frame: Up to 12 Weeks After the Last Dose ]
    Phase 1

  3. Incidence and severity of adverse events of special interest (AESI) with REGN5459 treatment period [ Time Frame: Up to 12 Weeks After the Last Dose ]
    Phase 1

  4. Objective response rate (ORR) as measured using the International Myeloma Working Group (IMWG) criteria [ Time Frame: Up to Approximately 104 Weeks ]
    Phase 2


Secondary Outcome Measures :
  1. Concentrations of REGN5459 in the serum over time [ Time Frame: Up to 12 Weeks After the Last Dose ]
    Phase 1 and phase 2

  2. Incidence over time of anti-drug antibodies (ADAs) to REGN5459 [ Time Frame: Up to 12 Weeks After the Last Dose ]
    Phase 1 and phase 2

  3. Duration of response (DOR) using the IMWG criteria [ Time Frame: Up to Approximately 104 Weeks ]
    Phase 1 and phase 2

  4. Progression-free survival (PFS) as measured using the IMWG criteria [ Time Frame: Up to Approximately 104 Weeks ]
    Phase 1 and phase 2

  5. Rate of minimal residual disease (MRD) negative status using the IMWG criteria [ Time Frame: Up to Approximately 104 Weeks ]
    Phase 1 and phase 2

  6. Overall survival (OS) [ Time Frame: Up to Approximately 104 Weeks ]
    Phase 1 and phase 2

  7. Patient-reported Quality of Life (QOL) per European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) [ Time Frame: Up to 12 Weeks After the Last Dose ]

    Phase 1 and phase 2

    The EORTC-QLQ-C30 is a 30-item subject self-report questionnaire composed of both multi-item and single scales, including global health status/quality of life, functional Scales (physical, role, emotional, cognitive, and social) , symptom scales (fatigue, nausea and vomiting, and pain), and 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). Participants rate items on a 4-point scale, with 1 as "not at all" and 4 as "very much."


  8. Patient-reported QOL per EORTC Quality of Life Questionnaire-Multiple Myeloma module 20 (EORTC QLQ-MY20) [ Time Frame: Up to 12 Weeks After the Last Dose ]

    Phase 1 and phase 2

    The EORTC QLQ-MY20 is a self-administered instrument to assess QoL in persons with MM. This 20-item questionnaire measures the following domains: symptom scales, including disease symptoms (6 items) and symptoms related to side effects of treatment (10 items); function scale and future perspective (3 items); and body image (1 item). A high score represents a high level of symptoms or problems.


  9. Patient-reported QOL per EuroQoL-5 Dimension-3 Level Scale (EQ-5D-3L) [ Time Frame: Up to 12 Weeks After the Last Dose ]

    Phase 1 and phase 2

    The EQ-5D-3L is a self-administered generic standardized health status measure, consisting of an EQ-5D descriptive system and an EQ visual analog scale. The EQ-5D-3L descriptive system assesses 5 dimensions of health: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension is rated on a 3-level scale: no problems, some problems, and extreme problems. The EQ visual analog scale component is a vertical visual analog scale used by patients to rate their health.


  10. Change in patient-reported global health status/QOL per EORTC QLQ-C30 [ Time Frame: Baseline up to 12 Weeks After the Last Dose ]

    Phase 1 and phase 2

    The EORTC-QLQ-C30 is a 30-item subject self-report questionnaire composed of both multi-item and single scales, including global health status/quality of life, functional Scales (physical, role, emotional, cognitive, and social) , symptom scales (fatigue, nausea and vomiting, and pain), and 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). Participants rate items on a 4-point scale, with 1 as "not at all" and 4 as "very much."


  11. Time to definitive deterioration in patient-reported global health status/QOL per EORTC QLQ-C30 [ Time Frame: Up to 12 Weeks After the Last Dose ]

    Phase 1 and phase 2

    The EORTC-QLQ-C30 is a 30-item subject self-report questionnaire composed of both multi-item and single scales, including global health status/quality of life, functional Scales (physical, role, emotional, cognitive, and social) , symptom scales (fatigue, nausea and vomiting, and pain), and 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). Participants rate items on a 4-point scale, with 1 as "not at all" and 4 as "very much."


  12. Change in patient-reported general health status per EQ-5D-3L [ Time Frame: Baseline up to 12 Weeks After the Last Dose ]

    Phase 1 and phase 2

    The EQ-5D-3L is a self-administered generic standardized health status measure, consisting of an EQ-5D descriptive system and an EQ visual analog scale. The EQ-5D-3L descriptive system assesses 5 dimensions of health: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension is rated on a 3-level scale: no problems, some problems, and extreme problems. The EQ visual analog scale component is a vertical visual analog scale used by patients to rate their health.


  13. ORR as measured using the IMWG criteria [ Time Frame: Up to Approximately 104 Weeks ]
    Phase 1 Only

  14. Incidence and severity of TEAEs during REGN5459 treatment period [ Time Frame: Up to 12 Weeks After the Last Dose ]
    Phase 2 Only

  15. Incidence and severity of AESI during REGN5459 treatment period [ Time Frame: Up to 12 Weeks After the Last Dose ]
    Phase 2 Only



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Key Inclusion Criteria:

  • Eastern Cooperative Oncology Group (ECOG) performance status ≤1
  • Patients must have myeloma that is response-evaluable according to the 2016 International Myeloma Working Group (IMWG) response criteria
  • Measurable disease is defined as 1 or more of the following:

    1. Serum M-protein ≥1 g/dL,
    2. Urine M-protein ≥200 mg/24-hour, and/or
    3. Free light chain (FLC) assay with involved FLC level ≥10 mg/dL with an abnormal serum FLC ratio
  • A patient with Immunoglobulin A (IgA) myeloma but without measurable M-protein may be enrolled if quantitative IgA levels are ≥400 mg/dL and can be followed longitudinally
  • A patient with non-secretory MM may be considered for enrollment after discussion with the sponsor that includes the feasibility of an individualized plan for response assessment
  • Patients with MM who have exhausted all therapeutic options that are expected to provide meaningful clinical benefit, either through disease relapse, treatment refractory disease, or intolerance of the therapy, and including either:

    1. Progression on or after at least 3 lines of therapy, or intolerance of therapy, including a proteasome inhibitor, an Immunomodulatory imide drug (IMiD), and an anti-CD38 antibody, OR
    2. Progression on or after an anti-CD38 antibody and having disease that is "double refractory" to a proteasome inhibitor and an IMiD, or intolerance of therapy. The anti-CD38 antibody may have been administered alone or in combination with another agent such as a proteasome inhibitor. Refractory disease is defined as lack of response or relapse within 60 days of last treatment.
  • Adequate hematologic function as measured by:

    1. Platelet count > 50 x 109/L. A patient may not have received a platelet transfusion within 7 days to meet this platelet eligibility requirement.
    2. ANC > 1.0 x 109/L. A patient may not have received granulocyte colony stimulating factor (G-CSF) within 2 days to meet this absolute neutrophil count eligibility requirement.
    3. Hemoglobin > 8.0 g/dL
  • Adequate hepatic function, defined as:

    1. Total bilirubin ≤1.5 x ULN
    2. Transaminase (ALT, AST) ≤2.5 x ULN
    3. Alkaline phosphatase ≤2.5 x ULN
  • Patients with Gilbert syndrome do not need to meet this total bilirubin requirement provided that the total bilirubin is unchanged from the baseline value.

    d. Serum creatinine clearance by Cockcroft-Gault >30 mL/min

  • A patient with a creatinine clearance by Cockcroft-Gault who does not meet eligibility criteria may be considered for enrollment if a measured creatinine clearance (based on 24-hour urine collection or other reliable method) is >30 mL/min
  • Life expectancy of at least 6 months

Key Exclusion Criteria:

  • Patients with known MM brain lesions or meningeal involvement
  • History of neurodegenerative condition or central nervous system (CNS) movement disorder, or patients with a history of seizure within 12 months before study enrollment are excluded
  • Cardiac ejection fraction <40% by echocardiogram or multi-gated acquisition scan (MUGA)
  • Prior treatment with any anti-BCMA antibody (including antibody-drug conjugate or bispecific antibody) or BCMA-directed CAR T therapy
  • Uncontrolled infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV) or hepatitis C virus (HCV) infection; or other uncontrolled infection

    1. Patients with HIV who have controlled infection (undetectable viral load and CD4 count above 350 cells/microliter either spontaneously or on a stable antiviral regimen) are permitted.
    2. Patients with hepatitis B (Hepatitis B Surface Antigen Test positive [HepBsAg+]) who have controlled infection (serum HBV DNA polymerase chain reaction [PCR] that is below the limit of detection AND receiving anti-viral therapy for hepatitis B) are permitted.
    3. Patients who are HCV antibody-positive (HCV Ab+) who have controlled infection (undetectable HCV RNA by polymerase chain reaction (PCR) either spontaneously or in response to a successful prior course of anti-HCV therapy) are permitted.
  • History of allogeneic stem cell transplantation at any time, or autologous stem cell transplantation within 12 weeks of the start of study treatment

NOTE: Other protocol defined Inclusion/Exclusion Criteria apply.


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04083534


Contacts
Layout table for location contacts
Contact: Clinical Trials Administrator 844-734-6643 clinicaltrials@regeneron.com

Locations
Layout table for location information
United States, Indiana
Regeneron Study Site Recruiting
Indianapolis, Indiana, United States, 46202
United States, Michigan
Regeneron Study Site Recruiting
Ann Arbor, Michigan, United States, 48109
United States, Minnesota
Regeneron Study Site Recruiting
Rochester, Minnesota, United States, 55905
United States, New York
Regeneron Study Site Recruiting
New York, New York, United States, 10029
United States, Texas
Regeneron Study Site Recruiting
Dallas, Texas, United States, 75390
Regeneron Study Site Recruiting
Houston, Texas, United States, 77030
United States, Wisconsin
Regeneron Study Site Recruiting
Milwaukee, Wisconsin, United States, 53226
Sponsors and Collaborators
Regeneron Pharmaceuticals
Investigators
Layout table for investigator information
Study Director: Clinical Trials Investigator Regeneron Pharmaceuticals
Layout table for additonal information
Responsible Party: Regeneron Pharmaceuticals
ClinicalTrials.gov Identifier: NCT04083534    
Other Study ID Numbers: R5459-ONC-1888
2019-001108-39 ( EudraCT Number )
First Posted: September 10, 2019    Key Record Dates
Last Update Posted: June 15, 2021
Last Verified: April 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: All individual patient data (IPD) that underlie publicly available results will be considered for sharing
Supporting Materials: Study Protocol
Statistical Analysis Plan (SAP)
Informed Consent Form (ICF)
Clinical Study Report (CSR)
Analytic Code
Time Frame: Individual anonymized participant data will be considered for sharing once the indication has been approved by a regulatory body, if there is legal authority to share the data and there is not a reasonable likelihood of participant re-identification.
Access Criteria: Qualified researchers may request access to anonymized patient level data or aggregate study data when Regeneron has received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc) for the product and indication, has the legal authority to share the data, and has made the study results publicly available (eg, scientific publication, scientific conference, clinical trial registry).
URL: https://errs.regeneron.com/external

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Multiple Myeloma
Neoplasms, Plasma Cell
Neoplasms by Histologic Type
Neoplasms
Hemostatic Disorders
Vascular Diseases
Cardiovascular Diseases
Paraproteinemias
Blood Protein Disorders
Hematologic Diseases
Hemorrhagic Disorders
Lymphoproliferative Disorders
Immunoproliferative Disorders
Immune System Diseases